Autoimmunity linked to COVID-19 immunization has been recorded throughout the
pandemic. Herein we present six new patients who experienced relapses of previous …

New evidence for the treatment of rheumatoid arthritis (RA) has emerged during the last
year. Specifically, updated guidelines on pharmacological and non-pharmacological …

Objectives Humoral vaccine responses to SARS-CoV-2 vaccines are impaired and short
lasting in patients with immune-mediated inflammatory diseases (IMID) following two …

Background Vaccines offer people with multiple sclerosis (PwMS) an effective protection
against severe COVID-19 disease courses. However, representative real-world data on the …

Objectives To compare the cumulative incidence and disease severity of reported SARS-
CoV-2 omicron breakthrough infections between patients with immune-mediated …

Background The safety of a third dose of SARS-CoV-2 mRNA vaccination in patients with
inflammatory bowel disease is unknown. Methods We compared symptoms following a third …

For patients with immune-mediated inflammatory diseases (IMIDs), concerns exist about
increased disease activity after vaccination. We aimed to assess changes in disease activity …

Implementing vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) is a major asset in slowing down the coronavirus disease 2019 (COVID-19) …

Background Patients with immune-mediated inflammatory diseases (IMIDs) on
immunosuppressants (ISPs) may have impaired long-term humoral immune responses and …

Objective To determine if coronavirus disease 2019 (COVID-19) vaccines were associated
with adverse events of special interest (AESIs) and healthcare use among adults with …